Rockwell Medical Inc. (NASDAQ:RMTI)’s share price was up 5.1% on Wednesday . The company traded as high as $8.06 and last traded at $8.03, with a volume of 101,735 shares changing hands. The stock had previously closed at $7.64.

RMTI has been the subject of several analyst reports. Zacks Investment Research raised shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Friday, May 13th. Morgan Stanley reissued a “sell” rating on shares of Rockwell Medical in a research report on Wednesday, April 6th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $10.17.

The stock has a 50 day moving average of $8.18 and a 200 day moving average of $7.82. The company’s market cap is $412.21 million.

Rockwell Medical (NASDAQ:RMTI) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.02. The business had revenue of $13.63 million for the quarter, compared to the consensus estimate of $15.25 million. Rockwell Medical’s revenue for the quarter was down 1.8% compared to the same quarter last year. During the same period last year, the business posted ($0.07) earnings per share. On average, equities analysts expect that Rockwell Medical Inc. will post ($0.27) EPS for the current fiscal year.

Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.